Please ensure Javascript is enabled for purposes of website accessibility

Eli Lilly Earns Landmark Approval for Alzheimer's Disease Imaging Agent

By Cory Renauer – May 28, 2020 at 8:52PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's not a treatment for this memory-robbing dementia, but it could help Lilly and its peers find one.

On Thursday, the Food and Drug Administration (FDA) approved the use of a radioactive diagnostic instrument for patients under evaluation for Alzheimer's disease. This drug from Eli Lilly (LLY -1.37%) is the first that the FDA has approved to look for tau neurofibrillary tangles (NFTs) in the brain.

What's it good for?

The number of Americans living with Alzheimer's disease is expected to rise from around 5 million in 2014 to around 14 million by 2060. There are no treatments proven to slow the progression of this ultimately fatal disease yet, but a better understanding of NFTs and their association with dementia could go a long way to help.

Physician examining a brain scan.

Image source: Getty Images.

Positron emission tomography (PET) images with lots of NFTs are a primary marker of Alzheimer's and other dementias, but so are amyloid plaques. Lilly and several of its peers have spent billions developing drugs that effectively reduce the formation of amyloid plaques, but this hasn't been proven to help slow down the progression of this ultimately fatal disease.

While NFTs have been associated with Alzheimer's disease at least as long as amyloid plaques, new drug candidates aimed at their reduction haven't been explored as often. Now that Tauvid has been approved by the FDA to help physicians and researchers track NFTs, we could see more development of drugs that aim in this direction.

Currently, the only way to definitively diagnose Alzheimer's is with a post-mortem evaluation of a patient's brain. Eli Lilly and the FDA found Tauvid to be safe and accurate in two trials with terminally ill patients that allowed their brains to undergo post-mortem evaluations following Tauvid imaging.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
$325.48 (-1.37%) $-4.53

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.